Neurogene at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Neurogene brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on AAV gene therapy for rare brain disorders. Topics include delivery straight into the cerebrospinal fluid becoming a standard route and how quickly expression and clinical benefit appear in Rett syndrome.
| Organization | ESGCT 2026 Attendance |
|---|---|
Neurogene New York, NY | |
Clinical-stage company developing AAV gene therapies for rare neurological diseases, including NGN-401 for Rett syndrome. | Poster Wed Oct 28 1:30pm–3:30pm Gene therapy targeting CNS diseases: ICV administration as a growing standard for delivery Poster Thu Oct 29 2:00pm–4:00pm Expression Kinetics and Clinical Onset of Benefit Following Single-Stranded AAV Delivery of NGN-401 in Rett Syndrome |
Instantly find 20 buyers from Neurogene
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction